The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.